Yoo Soo Jin, Park Chan Jeoung, Jang Seongsoo, Seo Eul-Ju, Lee Kyoo-Hyung, Chi Hyun Sook
Department of Laboratory Medicine, Sanggye Paik Hospital, Inje University, Seoul, Korea.
Leuk Lymphoma. 2006 Sep;47(9):1788-93. doi: 10.1080/10428190600687927.
Alterations of the FLT3 gene, in the form of internal tandem duplications (ITD) and D835 point mutations, occur frequently in acute promyelocytic leukemia (APL). We therefore evaluated the frequency and clinical relevance of FLT3 aberrations in a series of Korean APL patients. We assayed FLT3 ITD and D835 mutation status in 75 newly diagnosed APL patients and we correlated the presence of these mutations with clinical parameters and outcomes. Of the 75 patients, fifteen (20.0%) carried FLT3 mutations, nine (12.0%) with FLT3 ITD, seven (9.3%) with D835 mutations and one with both types. Patients presenting with higher leukocyte counts (>10 x 10(9)/L) had a significantly higher frequency of FLT3 ITD (P = 0.030). There was no association between FLT3 aberrations and other clinicohematologic features including age, gender, M3 variant morphology and PML/RARalpha subtype. Death at presentation before induction chemotherapy was significantly more frequent in patients with ITD than in those without ITD (33.3% vs. 4.5%, P = 0.020), but was not significantly related to the presence of D835 mutations (28.6% vs. 5.9%, P = 0.094). Both ITD and D835 mutations were associated with shortened event-free survival (P = 0.048 and P = 0.029, respectively), but there was no correlation between disease-free survival among the 61 patients who achieved complete remission and the presence of FLT3 mutations (P = 0.543 for ITD and P = 0.277 for D835). FLT3 mutations were less frequent in Korean APL patients than in Western APL patients. In Korean patients, however, FLT3 mutations were associated with higher leukemic burdens and early deaths before remission resulting in inferior prognosis.
FLT3基因以内部串联重复(ITD)和D835点突变的形式改变,在急性早幼粒细胞白血病(APL)中频繁出现。因此,我们评估了一系列韩国APL患者中FLT3畸变的频率及其临床相关性。我们检测了75例新诊断的APL患者的FLT3 ITD和D835突变状态,并将这些突变的存在与临床参数和预后相关联。75例患者中,15例(20.0%)携带FLT3突变,9例(12.0%)为FLT3 ITD,7例(9.3%)为D835突变,1例同时携带两种类型。白细胞计数较高(>10×10⁹/L)的患者中FLT3 ITD的频率显著更高(P = 0.030)。FLT3畸变与其他临床血液学特征(包括年龄、性别、M3变异形态和PML/RARα亚型)之间无关联。诱导化疗前就诊时死亡在ITD患者中比无ITD患者更频繁(33.3%对4.5%,P = 0.020),但与D835突变的存在无显著相关性(28.6%对5.9%,P = 0.094)。ITD和D835突变均与无事件生存期缩短相关(分别为P = 0.048和P = 0.029),但在61例获得完全缓解的患者中,无病生存期与FLT3突变的存在无相关性(ITD为P = 0.543,D835为P = 0.277)。韩国APL患者中FLT3突变的频率低于西方APL患者。然而,在韩国患者中,FLT3突变与更高的白血病负担和缓解前早期死亡相关,导致预后较差。